Pfizer discontinues PCSK9 program

In its 3Q16 earnings report, Pfizer Inc. (NASDAQ:PFE) said it will discontinue global development of PCSK9 inhibitor bococizumab (PF-4950615) and halt the SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs) of the candidate. The

Read the full 336 word article

User Sign In